Document is current
Any future updates will be listed below
-
Authors
De Velasco, Marco A.
Sakai, Kazuko
Mitani, Seiichiro
Kura, Yurie
Minamoto, Shuji
Haeno, Takahiro
Hayashi, Hidetoshi
Nishio, Kazuto https://orcid.org/0000-0002-8275-0846
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (23H02777)
- License Information
-
More Information
Article History
Received: 23 May 2024
Accepted: 28 August 2024
First Online: 18 September 2024
Declarations
:
: MAV received research funds from AstraZeneca. HH received lecture fees or honoraria from AstraZeneca, Bristol Myers Squibb, Amgen, Chugai Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, and Pfizer Japan, and research funds from PAREXEL International, Japan Clinical Research Operations, Daiichi Sankyo, AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Sysmex, Ono Pharmaceutical, Takeda Pharmaceutical, PPD-SNBL, Nippon Boehringer Ingelheim, SYNEOS HEALTH CLINICAL, IQVIA Services JAPAN, Covance Japan, GlaxoSmithKline, Sanofi and EPS, and scholarship from Chugai Pharmaceutical, Takeda Pharmaceutical, Ono Pharmaceutical, Eisai. KN received lecture fee from Chugai Pharmaceutical, and research funds from Nippon Boehringer Ingelheim, Clinical Research Support Center Kyushu, West Japan Oncology Group, Nichirei Biosciences, Osakaminami Hospital, Eli Lilly Japan, Hitachi, and Otsuka Pharmaceutical. Kazuto Nishio is an editorial board member of Cancer Science. The other authors have no conflict of interest.
: The research protocol was approved by the Ethical Review Board of Kindai University Faculty of Medicine (R05-006).
